Literature DB >> 3051125

Pharmacogenetics and its clinical implications. Part II. Oxidation polymorphism.

Y Horai, T Ishizaki.   

Abstract

Mesh：

Substances：

Year:  1988        PMID： 3051125

Source DB:  PubMed          Journal:  Ration Drug Ther        ISSN： 0031-7020


× No keyword cloud information.
  6 in total

Review 1.  Clinical trials and transethnic pharmacology.

Authors:  M E Kitler
Journal:  Drug Saf       Date:  1994-11       Impact factor: 5.606

2.  Genetically determined sparteine oxidation polymorphism in a Polish population.

Authors:  K Orzechowska-Juzwenko; J Pawlik; P Niewiński; P Milejski; J Dembowski; J Turek; A Goździk; L Swiebodzki; Z Hora
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 3.  Safety of potent gastric acid inhibition.

Authors:  Carlos Martín de Argila
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Oxidative polymorphism of debrisoquine is not related to human colo-rectal cancer.

Authors:  J M Ladero; J Benítez; J F González; E Vargas; M Díaz-Rubio
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

5.  Metoprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations.

Authors:  D R Sohn; S G Shin; C W Park; M Kusaka; K Chiba; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

Review 6.  Proton pump inhibitors in cirrhosis: tradition or evidence based practice?

Authors:  Francesca Lodato; Francesco Azzaroli; Maria Di Girolamo; Valentina Feletti; Paolo Cecinato; Andrea Lisotti; Davide Festi; Enrico Roda; Giuseppe Mazzella
Journal:  World J Gastroenterol       Date:  2008-05-21       Impact factor: 5.742
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.